Imeik Technology Development Co., Ltd.

Imeik Technology Development Co., Ltd. is an innovative enterprise based in China, specializing in the development and commercialization of biomedical soft tissue repairment materials. Founded in 2004 and listed on the ChiNext market of the Shenzhen Stock Exchange in 2020, the company focuses on research and development of genetically recombinant proteins, polypeptides, and biopharmaceuticals. It has achieved significant milestones in the mass commercialization of hyaluronic acid-based dermal fillers and has established a robust product technology transformation platform for various biomedical materials. The company's main business lines include the R&D, manufacturing, and marketing of biomedical materials, particularly in the medical aesthetics sector. Imeik has developed a diverse range of products, including several firsts in the Chinese market, such as the first HA-based dermal filler and the first facial implant thread approved by the National Medical Products Administration. With a strong emphasis on technology innovation and a direct sales model, Imeik has built a comprehensive sales network across China, serving over 4,000 medical aesthetic institutions and fostering long-term relationships with its customers.

The Company has specialized in the R&D, manufacturing and commercialization of biomedical materials, and has accumulated key competitive advantages including such in technology, products, sales channel, customer resources and global vision. These key competitive advantages have fueled its business growth and enhanced its brand recognition, as follows: (1)Technology Since its establishment, the Company has prioritized technology innovation and adopted an R&D model that integrates production, academia, R&D and medical application. The Company has set up a platform for the transformation of biomedical materials and products through its Beijing engineering laboratory for new biodegradable materials. The Company, as the leading organization, participated in the R&D project to advance the discovery of new repairment materials for soft and hard maxillofacial tissue, a key R&D plan initiated by the Ministry of Science and Technology of the PRC under the National Thirteenth Five-Year Key Research Plan. The Company continues to increase its investment in R&D and enhances its technology and innovation capabilities, which reinforced the Company's technology leadership in the field of medical soft tissue repairment materials. (2)Product The Company has in-house developed and launched seven products to target wrinkles treatment on the face and neck, including the first HA-based dermal filler (EME) made and commercialized in China, the first dermal filler containing PVA microspheres with long lasting filling effect in China (Bonita), the first lidocaine dermal filler made and commercialized in China (I Fresh), the first dermal filler commercialized to treat necklines in China (Hearty), the new composite material dermal filler (EME Plus), the first facial implant thread product approved in China (Tightly) and the first PLLA-PEG dermal filler approved in China (CureWhite), all of which contributed to the Company’s first-mover advantage. The Company’s products differentiate from each other in terms of their formulation, injection site, and effects, and can meet the diverse consumer needs of different market segments. (3)Sales Channel The Company adopts a direct sales-oriented sales model supplemented by distributorship and views its marketing capabilities as one of its key competitive strengths. The Company has developed a complete and effective training system for sales personnel, established a qualified and efficient sales and marketing team, and formed a sales network headquartered in Beijing and covering 31 provinces, cities and autonomous regions in China. The Company has fostered long-term and stable relationship with customers, responded quickly to customer needs, provided customers with customized product solutions and full-cycle supportive services, and enhanced customer satisfaction and loyalty. (4)Customer Resources The Company has been committed to forging a mutually beneficial relationship with customers and continued to strengthen its customer profile. The Company’s products have been adopted by a broad chain of premium private medical aesthetic institutions and certain Class III Grade A hospitals, including Plastic Surgery Hospital of Chinese Academy of Medical Sciences, and the China-Japan Friendship Hospital. As of September 30, 2021, its products had been adopted by over 4,000 medical aesthetic institutions nationwide. Such collaboration with its customers has contributed to the Company’s brand image and long-term development. (5)Global Vision The Company has a management and R&D team with a global vision, paying close attention to the R&D results and latest trends of the industry, including the development, innovations and application of biopharmaceuticals globally. Based on its current capabilities, the Company has adopted forward-looking technology and product development strategies, which allows the Company to obtain the first-mover advantage in the industry and achieve sustainable growth.